Figure 2.

(A) Individual response map of patients in Delta-radiomics sub-cohort. Bars indicate the changes of total tumor burden between baseline and TP1 CT scans. Patients are grouped on the basis of therapy response at TP1 following iRECIST criteria (Complete response [CR] in green, partial response [PR] in blue, stable disease [SD] in gray, and unconfirmed progression [iUPD] in purple). In addition, hyper-progression (n = 1, in red) and pseudo-progression (n = 8, in orange) are noted as well. (B) Sankey diagram depicts therapy response alternation flow within follow-up interval. For those patients who met the progression threshold (20% increasement of tumor burden) at any time point within follow-up interval, updated response labels are attached according to their subsequent assessment (Confirmed progression [iCPD], stable disease [iSD], and partial response [iPR]). It’s noteworthy that for those patients who were thought to be iUPD at 6-month, their labels were determined by additional follow-ups so that any unconfirmed progression would not be used as labels in model training. (C, D) Nomograms of largest target lesion model (in blue) and target lesions model (in red) which were developed in training set respectively.